Immunovant Inc. (IMVT), which reported positive results from its myasthenia gravis and chronic inflammatory demyelinating polyneuropathy studies of Batoclimab in March of this year, has two more key clinical readouts on the horizon.
Batoclimab works by targeting a specific protein in the body called the neonatal fragment crystallizable receptor (FcRn), which helps regulate the levels of immunoglobulin G (IgG) antibodies in the blood by preventing IgG degradation. In healthy people, IgG antibodies recognize and bind to foreign substances, marking them for destruction. In many autoimmune diseases, however, harmful IgG autoantibodies develop, triggering a harmful immune response where they recognize and bind to normal healthy tissue. By blocking FcRn, Batoclimab can reduce the levels of harmful antibodies that cause autoimmune diseases.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.